SignalXSignalX

Altimmune, Inc. (ALT) 8-K Current Report: March 5, 2026

Filed: March 5, 2026
Health Care
Pharmaceutical Preparations
Altimmune, Inc. Overview

Altimmune, Inc. (ALT) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

Altimmune, Inc. 8-K Mar 5, 2026 Event Analysis

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 earnings announced March 5, 2026; full results in Exhibit 99.1 press release
  • • Reporting period: fiscal year ended December 31, 2025
  • • Item 2.02 filing signals results are furnished (not filed), meaning no SEC liability attached to the figures

Get deeper insights on Altimmune, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.